Fig. 5

In vivo tumor therapy and immune response activation by CussOMEp (300 µg per mouse). (a) Schematic representation of the treatment schedule. (b, c) Tumor growth curves showing individual (b) and total (c) tumor sizes (n = 4). (d-f) Tumor weight (d), corresponding images (e), and TGI values (f) in mice post treatments on day 14. (g) H&E staining and IHC staining for HIF-1α, FDX1, and GPX4 in tumor sections. (h) Percentage of M2 macrophages identified by flow cytometry (gated on CD11b⁺F4/80⁺CD206⁺). (i, j) Flow cytometry plots (i) and statistical analysis (j) of DC maturation in lymph nodes (gated on CD11c⁺CD80⁺CD86⁺). (k-n) Quantitative results for CD4⁺ T cells (CD3⁺CD4⁺), CD8⁺ T cells (CD3⁺CD8⁺), neutrophils (CD11b⁺F4/80⁺Ly6G⁺), and B cells (B220⁺). Statistical significance is indicated as *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, and ns (not significant, P > 0.05), determined by one-way ANOVA with Dunnett’s multiple comparisons test. Data are presented as mean ± s.d